Abstract At Vivlion, we continually strive to enhance CRISPR library and screening solutions. We introduce Alexandria, our flagship genome-wide PRCISR™ CRISPR knockout library, available in single-targeting and fixed-pair formats. The fixed-pair design delivers two sgRNAs per cell for the same gene (or predefined gene pairs), boosting editing efficiency and enabling combinatorial strategies. Alexandria broadens discovery by including ∼1,800 newly annotated genes overlooked by previous reagents and covers 20,381 genes (∼99.8% of ENSEMBL) with 4 sgRNAs per gene (2 pairs) to support confident hit calling across cell types and states. All PRCISR™ libraries are produced with Vivlion’s 3Cs technology, which utilizes the oligo pool directly and avoids PCR bias and cloning artefacts—yielding highly uniform gRNA distributions that preserve representation even in down-scaled screens (e.g., limited primary or iPSC material). Building on this, our library formats decouple sequence diversity from distribution, so users can deploy single-targeting, fixed-pair, or multiplex designs as their biology demands. In practice, Alexandria enables researchers to identify context-dependent dependencies, explore pathway mechanisms, paralog buffering, and prioritise actionable targets that standard screens may miss. To streamline execution, Vivlion offers pooled and optical pooled screening, bioinformatics support, leveraging ReCo, our automated NGS read-counting pipeline for single and combinatorial CRISPR data that simplifies downstream analysis. By combining advanced CRISPR screening with uniform, low-coverage reagents like Alexandria, researchers can accelerate discovery across disease and non-disease contexts alike. Citation Format: Elena Vialetto, Ronay Cetin, Sebastian Süsser, Simran Rastogi, Angela Hinchie, Jessica Martyn, Martin Wegner, Manuel Kaulich. The perturbation data gap: Accelerating discovery with CRISPR screening abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 498.
Vialetto et al. (Fri,) studied this question.